{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T11:45:45Z","timestamp":1762083945254,"version":"build-2065373602"},"reference-count":33,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2022,12,26]],"date-time":"2022-12-26T00:00:00Z","timestamp":1672012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Penile squamous cell carcinoma is a rare disease entity with poor overall survival in an advanced stage. Few studies have investigated the role of immunotherapy in advanced penile squamous cell carcinoma. Herein, we report a case of stage IV unresectable penile squamous cell carcinoma presenting with anal bleeding and urethra obstruction who responded dramatically to combination therapy of durvalumab and cisplatin-based chemotherapy. The patient had HPV-positive penile squamous cell carcinoma, cT3N3M0, with concomitant anus squamous cell carcinoma. After 2 months of the combination treatment, almost all bulky inguinal lymph nodes shrank, and the main tumor of the anus and penis responded completely. A durable response was seen 16 months after initiating the combination therapy. This case report highlights the potential role of the combination of immunotherapy and chemotherapy in patients with advanced penile cancer. The promising results of this combination resulted in the conversion of unresectable disease to a potentially curable disease.<\/jats:p>","DOI":"10.3390\/curroncol30010026","type":"journal-article","created":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T07:33:33Z","timestamp":1672126413000},"page":"326-332","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Combination of Durvalumab and Chemotherapy to Potentially Convert Unresectable Stage IV Penile Squamous Cell Carcinoma to Resectable Disease: A Case Report"],"prefix":"10.3390","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0153-1570","authenticated-orcid":false,"given":"Hao Xiang","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Urology, China Medical University Hospital, China Medical University, Taichung 40402, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ching-Chan","family":"Lin","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, China Medical University, Taichung 404, Taiwan"},{"name":"Division of Hematology and Oncology, Department of Internal Medicine, An Nan Hospital, China Medical University, Tainan 709, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Che-Hung","family":"Lin","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, China Medical University, Taichung 404, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi-Rei","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Urology, China Medical University Hospital, China Medical University, Taichung 40402, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,12,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1002\/ijc.31937","article-title":"Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods","volume":"144","author":"Ferlay","year":"2019","journal-title":"Int. J. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s10552-008-9276-9","article-title":"Systematic review of human papillomavirus prevalence in invasive penile cancer","volume":"20","author":"Backes","year":"2008","journal-title":"Cancer Causes Control"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s00345-011-0802-0","article-title":"Epidemiologic profile, sexual history, pathologic features, and human papillomavirus status of 103 patients with penile carcinoma","volume":"31","author":"Chaux","year":"2011","journal-title":"World J. Urol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/j.vaccine.2006.05.111","article-title":"Chapter 2: The burden of HPV-related cancers","volume":"24","author":"Parkin","year":"2006","journal-title":"Vaccine"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1471-2407-12-30","article-title":"Estimation of the epidemiological burden of human papillomavirus-related cancers and non-malignant diseases in men in Europe: A review","volume":"12","author":"Hartwig","year":"2012","journal-title":"BMC Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3109\/00365599.2012.677473","article-title":"Initial symptoms and delay in patients with penile carcinoma","volume":"46","author":"Skeppner","year":"2012","journal-title":"Scand. J. Urol. Nephrol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s12957-016-0863-z","article-title":"Risk factors and negative consequences of patient\u2019s delay for penile carcinoma","volume":"14","author":"Gao","year":"2016","journal-title":"World J. Surg. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/j.1464-410X.1993.tb16273.x","article-title":"Correlation between the Extent of Nodal Involvement and Survival following Groin Dissection for Carcinoma of the Penis","volume":"72","author":"Ravi","year":"1993","journal-title":"BJU Int."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.juro.2013.07.088","article-title":"Contemporary Management of Regional Nodes in Penile Cancer\u2014Improvement of Survival?","volume":"191","author":"Djajadiningrat","year":"2014","journal-title":"J. Urol."},{"key":"ref_11","first-page":"E661","article-title":"Cisplatin and 5-fluorouracil in inoperable, stage IV squamous cell carcinoma of the penis","volume":"110","author":"Buonerba","year":"2012","journal-title":"BJU Int."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3851","DOI":"10.1200\/JCO.2010.29.5477","article-title":"Neoadjuvant Paclitaxel, Ifosfamide, and Cisplatin Chemotherapy for Metastatic Penile Cancer: A Phase II Study","volume":"28","author":"Pagliaro","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.urology.2010.03.082","article-title":"Treatment of Visceral, Unresectable, or Bulky\/Unresectable Regional Metastases of Penile Cancer","volume":"76","author":"Pettaway","year":"2010","journal-title":"Urology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"4","DOI":"10.4103\/UROS.UROS_11_19","article-title":"Rational combination with an immunotherapy backbone in genitourinary cancers","volume":"31","author":"Lin","year":"2020","journal-title":"Urol. Sci."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/CJI.0000000000000221","article-title":"Evidence for Efficacy of Treatment with the Anti-PD-1 Mab Nivolumab in Radiation and Multichemorefractory Advanced Penile Squamous Cell Carcinoma","volume":"41","author":"Trafalis","year":"2018","journal-title":"J. Immunother."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"615298","DOI":"10.3389\/fonc.2020.615298","article-title":"Case Report: Two Cases of Chemotherapy Refractory Metastatic Penile Squamous Cell Carcinoma with Extreme Durable Response to Pembrolizumab","volume":"10","author":"Chahoud","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.asjsur.2021.12.048","article-title":"Neoadjuvant tislelizumab combination chemotherapy for advanced penile cancer: A case report","volume":"45","author":"Dou","year":"2022","journal-title":"Asian J. Surg."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1038\/s41591-021-01444-0","article-title":"Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: A multicenter randomized phase 3 trial","volume":"27","author":"Mai","year":"2021","journal-title":"Nat. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/S1470-2045(21)00302-8","article-title":"Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): A multicentre, randomised, double-blind, phase 3 trial","volume":"22","author":"Yang","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa2112435","article-title":"Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer","volume":"385","author":"Colombo","year":"2021","journal-title":"New Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1016\/j.clgc.2019.10.014","article-title":"PD-L1 and p16 Expression in Penile Squamous Cell Carcinoma from an Endemic Region","volume":"18","author":"Carvalhal","year":"2020","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1093\/annonc\/mdw216","article-title":"Frequent PD-L1 expression in primary and metastatic penile squamous cell carcinoma: Potential opportunities for immunotherapeutic approaches","volume":"27","author":"Udager","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1158\/1535-7163.MCT-14-0983","article-title":"PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy","volume":"14","author":"Patel","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"8024","DOI":"10.1200\/jco.2014.32.15_suppl.8024","article-title":"First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: Safety, efficacy, and correlation of outcomes with PD-L1 status","volume":"32","author":"Gettinger","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"iv375","DOI":"10.1093\/annonc\/mdu344.4","article-title":"Long-Term Survival of Ipilimumab-Na&#xef;ve Patients (Pts) with Advanced Melanoma (Mel) Treated with Nivolumab (Anti-Pd-1; Bms-936558, Ono-4538) in a Phase 1 Trial","volume":"25","author":"McDermott","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.juro.2016.09.088","article-title":"Expression of Programmed Death Ligand 1 in Penile Cancer is of Prognostic Value and Associated with HPV Status","volume":"197","author":"Ottenhof","year":"2017","journal-title":"J. Urol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1634\/theoncologist.2019-0244","article-title":"Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence","volume":"25","author":"Klempner","year":"2020","journal-title":"Oncologist"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of Pembrolizumab in Patients with Noncolorectal High Microsatellite Instability\/Mismatch Repair\u2013Deficient Cancer: Results from the Phase II KEYNOTE-158 Study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1007\/s10637-021-01100-x","article-title":"Pembrolizumab for advanced penile cancer: A case series from a phase II basket trial","volume":"39","author":"Hahn","year":"2021","journal-title":"Investig. New Drugs"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/cncr.33328","article-title":"Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies","volume":"127","author":"McGregor","year":"2021","journal-title":"Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1200\/JCO.2022.40.6_suppl.003","article-title":"Clinical results of PERICLES: A phase II trial investigating atezolizumab +\/- radiotherapy for advanced squamous cell carcinoma of the penis","volume":"40","author":"Vries","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.annonc.2020.07.002","article-title":"The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) \u226510: A decision centered on empowering patients and their physicians","volume":"31","author":"Subbiah","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/j.juro.2006.11.038","article-title":"Neoadjuvant chemotherapy followed by aggressive surgical consolidation for metastatic penile squamous cell carcinoma","volume":"177","author":"Bermejo","year":"2007","journal-title":"J. Urol."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/30\/1\/26\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:51:24Z","timestamp":1760147484000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/30\/1\/26"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,26]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["curroncol30010026"],"URL":"https:\/\/doi.org\/10.3390\/curroncol30010026","relation":{},"ISSN":["1718-7729"],"issn-type":[{"type":"electronic","value":"1718-7729"}],"subject":[],"published":{"date-parts":[[2022,12,26]]}}}